Nuvalent, Inc. - Class A Common Stock (NUVL)

Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial.

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.

NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the second quarter of 2024.

Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental drug.

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Nuvalent (NUVL) reported Q2 2025 EPS of -$1.31, slightly missing estimates, with no revenue as expected. Shares rose pre-market as investors focus on its oncology pipeline, including zidesamtinib's NDA submission.

Nuvalent releases pivotal ARROS-1 trial data and plans to begin a rolling NDA submission for zidesamtinib in July 2025.

The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in 2025.

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.

Although short-squeeze stocks to buy present great risk, betting against the bears can also yield dramatically robust returns.

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.